Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 2/2018

20.12.2017

MiR-411 suppressed vein wall fibrosis by downregulating MMP-2 via targeting HIF-1α

verfasst von: Peng Ai, Bangli Shen, Hao Pan, Kui Chen, Jihang Zheng, Fengjun Liu

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

This study was aim to investigate the specific mechanisms of miR-411 in vein wall fibrosis remodeling. Vein wall fibrosis injury-induced deep venous thrombosis (DVT) rat model was well established. The expression of miR-411 at mRNA levels and Collagen I, hypoxia-inducible factor (HIF)-1α together with matrix metalloproteinase (MMP)-2 at protein levels in vein wall tissues and vascular smooth muscle cells (VSMCs) following transfection were determined using quantitative real-time PCR (qRT-PCR) and western blotting, respectively. Luciferase reporter assay was used to confirm the potential target of miR-411. MiR-411 mimic injected into rat model of DVT was to verify the role of miR-411 in vein wall fibrosis in vivo. MiR-411 was downregulated while Collagen I, HIF-1α and MMP-2 was upregulated in vein wall tissues and VSMCs obtained from rat model of DVT. MiR-411 overexpression in VSMCs separated from rats of vascular remodeling group (VR-VSMCs) upregulated miR-411, HIF-1α and inhibited cell proliferation and Collagen I expression, while miR-411 knockdown in VSMCs isolated from healthy rats (Control-VSMCs) reversed the effects. Furthermore, luciferase reporter assay demonstrated that HIF-1α was a target of miR-411. In addition, overexpression of miR-411 and HIF-1α in VR-VSMCs promoted HIF-1α, Collagen I expression and cell proliferation, however, tissue inhibitor of metalloproteinase (TIMP)-2 treatment led to adverse trends. MiR-411 mimic injected into rat model of DVT could suppress vein wall fibrosis in vivo. MiR-411 inhibited vein wall fibrosis by downregulating MMP-2 mediated by HIF-1α.
Literatur
1.
Zurück zum Zitat Undas A (2017) Prothrombotic fibrin clot phenotype in patients with deep vein thrombosis and pulmonary embolism: a new risk factor for recurrence. BioMed Res Int 2017:8196256CrossRefPubMedPubMedCentral Undas A (2017) Prothrombotic fibrin clot phenotype in patients with deep vein thrombosis and pulmonary embolism: a new risk factor for recurrence. BioMed Res Int 2017:8196256CrossRefPubMedPubMedCentral
2.
3.
Zurück zum Zitat Min SK, Kim YH, Joh JH, Kang JM, Park UJ, Kim HK, Chang JH, Park SJ, Kim JY, Bae JI, Choi SY, Kim CW, Park SI, Yim NY, Jeon YS, Yoon HK, Park KH (2016) Diagnosis and treatment of lower extremity deep vein thrombosis: Korean practice guidelines. Vasc Spec Int 32(3):77–104CrossRef Min SK, Kim YH, Joh JH, Kang JM, Park UJ, Kim HK, Chang JH, Park SJ, Kim JY, Bae JI, Choi SY, Kim CW, Park SI, Yim NY, Jeon YS, Yoon HK, Park KH (2016) Diagnosis and treatment of lower extremity deep vein thrombosis: Korean practice guidelines. Vasc Spec Int 32(3):77–104CrossRef
4.
Zurück zum Zitat Xavier FD, Hoff PMG, Braghiroli MI, Paterlini A, Souza KT, Faria L, Ferreira FSB, Machado KK, Fernandes GDS (2017) Rivaroxaban: an affordable and effective alternative in cancer-related thrombosis? J Glob Oncol 3(1):15–22CrossRefPubMed Xavier FD, Hoff PMG, Braghiroli MI, Paterlini A, Souza KT, Faria L, Ferreira FSB, Machado KK, Fernandes GDS (2017) Rivaroxaban: an affordable and effective alternative in cancer-related thrombosis? J Glob Oncol 3(1):15–22CrossRefPubMed
5.
Zurück zum Zitat Sharma M, Ramanathan S, Khalighi K (2017) Development of new deep venous thrombosis while on apixaban. Case Rep Cardiol 2017:2842935PubMedPubMedCentral Sharma M, Ramanathan S, Khalighi K (2017) Development of new deep venous thrombosis while on apixaban. Case Rep Cardiol 2017:2842935PubMedPubMedCentral
6.
Zurück zum Zitat Toratani M, Hayashi A, Nishiyama N, Nakamura H, Chida R, Komatsu T, Nakahara S, Kobayashi S, Taguchi I (2017) Thrombosis in an internal jugular vein and an upper limb deep vein treated with edoxaban. Intern Med 56(9):1053–1055CrossRefPubMedPubMedCentral Toratani M, Hayashi A, Nishiyama N, Nakamura H, Chida R, Komatsu T, Nakahara S, Kobayashi S, Taguchi I (2017) Thrombosis in an internal jugular vein and an upper limb deep vein treated with edoxaban. Intern Med 56(9):1053–1055CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Listed N (2013) Deep venous thrombosis and pulmonary embolism. Part 2—Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months. Prescrire Int 22(138):129–33 Listed N (2013) Deep venous thrombosis and pulmonary embolism. Part 2—Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months. Prescrire Int 22(138):129–33
8.
Zurück zum Zitat Adams MK, Anaya-Ayala JE, Ismail N, Peden EK (2012) Surgical femorocaval bypass for recalcitrant iliofemoral venous occlusion to endovascular treatment. Vasc Endovasc Surg 46(7):578–81CrossRef Adams MK, Anaya-Ayala JE, Ismail N, Peden EK (2012) Surgical femorocaval bypass for recalcitrant iliofemoral venous occlusion to endovascular treatment. Vasc Endovasc Surg 46(7):578–81CrossRef
9.
Zurück zum Zitat Khanna AK, Singh S (2012) Postthrombotic syndrome: surgical possibilities. Thrombosis 2012:520604CrossRefPubMed Khanna AK, Singh S (2012) Postthrombotic syndrome: surgical possibilities. Thrombosis 2012:520604CrossRefPubMed
10.
Zurück zum Zitat Duan PF, Ni CF (2016) Randomized study of different approaches for catheter-directed thrombolysis for lower-extremity acute deep venous thrombosis. J Formos Med Assoc = Taiwan yi zhi 115(8):652–657CrossRefPubMed Duan PF, Ni CF (2016) Randomized study of different approaches for catheter-directed thrombolysis for lower-extremity acute deep venous thrombosis. J Formos Med Assoc = Taiwan yi zhi 115(8):652–657CrossRefPubMed
11.
Zurück zum Zitat Wang W, Wu Y, Fang T, Xu D (2017) Thrombectomy combined with indwelling-catheter thrombolysis is more effective than pure thrombectomy for the treatment of lower extremity deep venous thrombosis. Open Med 12:177–183 Wang W, Wu Y, Fang T, Xu D (2017) Thrombectomy combined with indwelling-catheter thrombolysis is more effective than pure thrombectomy for the treatment of lower extremity deep venous thrombosis. Open Med 12:177–183
12.
Zurück zum Zitat Kahn SR, Galanaud JP, Vedantham S, Ginsberg JS (2016) Guidance for the prevention and treatment of the post-thrombotic syndrome. J Thromb Thrombolysis 41(1):144–53CrossRefPubMedPubMedCentral Kahn SR, Galanaud JP, Vedantham S, Ginsberg JS (2016) Guidance for the prevention and treatment of the post-thrombotic syndrome. J Thromb Thrombolysis 41(1):144–53CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Hunt PS (1969) Pathogenesis and conservative management of venous thrombosis and pulmonary embolism. Ulster Med J 38(1):76–87PubMedPubMedCentral Hunt PS (1969) Pathogenesis and conservative management of venous thrombosis and pulmonary embolism. Ulster Med J 38(1):76–87PubMedPubMedCentral
14.
Zurück zum Zitat Puskas A, Balogh Z, Hadadi L, Imre M, Orban E, Kosa K, Brassai Z, Mousa SA (2007) Spontaneous recanalization in deep venous thrombosis: a prospective duplex ultrasound study. Int Angiol 26(1):53–63PubMed Puskas A, Balogh Z, Hadadi L, Imre M, Orban E, Kosa K, Brassai Z, Mousa SA (2007) Spontaneous recanalization in deep venous thrombosis: a prospective duplex ultrasound study. Int Angiol 26(1):53–63PubMed
15.
Zurück zum Zitat Baldwin JF, Sood V, Elfline MA, Luke CE, Dewyer NA, Diaz JA, Myers DD, Wakefield T, Henke PK (2012) The role of urokinase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis. J Vasc Surg 56(4):1089–1097CrossRefPubMedPubMedCentral Baldwin JF, Sood V, Elfline MA, Luke CE, Dewyer NA, Diaz JA, Myers DD, Wakefield T, Henke PK (2012) The role of urokinase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis. J Vasc Surg 56(4):1089–1097CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Bonnans C, Chou J, Werb Z (2014) Remodelling the extracellular matrix in development and disease, Nature reviews. Mol Cell Biol 15(12):786–801 Bonnans C, Chou J, Werb Z (2014) Remodelling the extracellular matrix in development and disease, Nature reviews. Mol Cell Biol 15(12):786–801
17.
Zurück zum Zitat Cui N, Hu M, Khalil RA (2017) Biochemical and biological attributes of matrix metalloproteinases. Prog Mol Biol Transl Sci 147 1–73CrossRefPubMed Cui N, Hu M, Khalil RA (2017) Biochemical and biological attributes of matrix metalloproteinases. Prog Mol Biol Transl Sci 147 1–73CrossRefPubMed
18.
Zurück zum Zitat Deatrick KB, Obi A, Luke CE, Elfline MA, Sood V, Upchurch GR Jr, Jaffer F, Wakefield TW, Henke PK (2013) Matrix metalloproteinase-9 deletion is associated with decreased mid-term vein wall fibrosis in experimental stasis DVT. Thromb Res 132(3):360–366CrossRefPubMedPubMedCentral Deatrick KB, Obi A, Luke CE, Elfline MA, Sood V, Upchurch GR Jr, Jaffer F, Wakefield TW, Henke PK (2013) Matrix metalloproteinase-9 deletion is associated with decreased mid-term vein wall fibrosis in experimental stasis DVT. Thromb Res 132(3):360–366CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Wang G, Zhang Y, Zhao X, Meng C, Ma L, Kong Y (2015) MicroRNA-411 inhibited matrix metalloproteinase 13 expression in human chondrocytes. Am J Transl Res 7(10):2000–2006PubMedPubMedCentral Wang G, Zhang Y, Zhao X, Meng C, Ma L, Kong Y (2015) MicroRNA-411 inhibited matrix metalloproteinase 13 expression in human chondrocytes. Am J Transl Res 7(10):2000–2006PubMedPubMedCentral
20.
Zurück zum Zitat Zhang Y, Xu G, Liu G, Ye Y, Zhang C, Fan C, Wang H, Cai H, Xiao R, Huang Z (2016) miR-411–5p inhibits proliferation and metastasis of breast cancer cell via targeting GRB2. Biochem Biophys Res Commun 476(4):607CrossRefPubMed Zhang Y, Xu G, Liu G, Ye Y, Zhang C, Fan C, Wang H, Cai H, Xiao R, Huang Z (2016) miR-411–5p inhibits proliferation and metastasis of breast cancer cell via targeting GRB2. Biochem Biophys Res Commun 476(4):607CrossRefPubMed
21.
Zurück zum Zitat Wang B, Ding YM, Fan P, Wang B, Xu JH, Wang WX (2014) Expression and significance of MMP2 and HIF-1alpha in hepatocellular carcinoma. Oncol Lett 8(2):539–546CrossRefPubMedPubMedCentral Wang B, Ding YM, Fan P, Wang B, Xu JH, Wang WX (2014) Expression and significance of MMP2 and HIF-1alpha in hepatocellular carcinoma. Oncol Lett 8(2):539–546CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Deatrick KB, Obi A, Luke CE, Elfline MA, Sood V, Jr UG, Jaffer F, Wakefield TW, Henke PK (2013) Matrix metalloproteinase-9 deletion is associated with decreased mid-term vein wall fibrosis in experimental stasis DVT. Thromb Res 132(3):360–366CrossRefPubMedPubMedCentral Deatrick KB, Obi A, Luke CE, Elfline MA, Sood V, Jr UG, Jaffer F, Wakefield TW, Henke PK (2013) Matrix metalloproteinase-9 deletion is associated with decreased mid-term vein wall fibrosis in experimental stasis DVT. Thromb Res 132(3):360–366CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Diaz JA, Obi AT, Myers DD Jr, Wrobleski SK, Henke PK, Mackman N, Wakefield TW (2012) Critical review of mouse models of venous thrombosis. Arterioscler Thromb Vasc Biol 32(3):556–62CrossRefPubMedPubMedCentral Diaz JA, Obi AT, Myers DD Jr, Wrobleski SK, Henke PK, Mackman N, Wakefield TW (2012) Critical review of mouse models of venous thrombosis. Arterioscler Thromb Vasc Biol 32(3):556–62CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Lu Y, Ma B, Guo R, Wang Y, Zhang J, Wu Y, Pang G, Xin J, Ye W, Zou Y, Wang X, Hitos K, Curtin P, Fletcher J (2007) Deep vein thrombosis in trauma: a prospective study of lower limb orthopedic trauma patients in Tianjin Hospital, China. Int Angiol 26(2):165–70PubMed Lu Y, Ma B, Guo R, Wang Y, Zhang J, Wu Y, Pang G, Xin J, Ye W, Zou Y, Wang X, Hitos K, Curtin P, Fletcher J (2007) Deep vein thrombosis in trauma: a prospective study of lower limb orthopedic trauma patients in Tianjin Hospital, China. Int Angiol 26(2):165–70PubMed
25.
Zurück zum Zitat Evans CE, Humphries J, Wadoodi A, Waltham M, Burnand KG, Smith A (2010) Hypoxia and hypoxia-inducible factor 1 may have a role in venous thrombus resolution. Brit J Surg 96(S1):9 Evans CE, Humphries J, Wadoodi A, Waltham M, Burnand KG, Smith A (2010) Hypoxia and hypoxia-inducible factor 1 may have a role in venous thrombus resolution. Brit J Surg 96(S1):9
26.
Zurück zum Zitat Qin J, Liang H, Shi D, Dai J, Xu Z, Chen D, Chen X, Jiang Q (2015) A panel of microRNAs as a new biomarkers for the detection of deep vein thrombosis. J Thromb Thrombolysis 39(2):215CrossRefPubMed Qin J, Liang H, Shi D, Dai J, Xu Z, Chen D, Chen X, Jiang Q (2015) A panel of microRNAs as a new biomarkers for the detection of deep vein thrombosis. J Thromb Thrombolysis 39(2):215CrossRefPubMed
27.
Zurück zum Zitat Meng Q, Wang W, Yu X, Li W, Kong L, Qian A, Li C, Li X (2015) Upregulation of MicroRNA-126 contributes to endothelial progenitor cell function in deep vein thrombosis via its target PIK3R2. J Cell Biochem 116(8):1613–1623CrossRefPubMed Meng Q, Wang W, Yu X, Li W, Kong L, Qian A, Li C, Li X (2015) Upregulation of MicroRNA-126 contributes to endothelial progenitor cell function in deep vein thrombosis via its target PIK3R2. J Cell Biochem 116(8):1613–1623CrossRefPubMed
28.
Zurück zum Zitat Liu HP, Zhao XL, Wu XM, Zhou RD, Li HK, Li XG (2012) Hypoxia-inducible factor-1 expression in thrombosis and thrombolysis of a rabbit model of traumatic deep vein thrombosis. Chin J Tissue Eng Res 16:7929–7932 Liu HP, Zhao XL, Wu XM, Zhou RD, Li HK, Li XG (2012) Hypoxia-inducible factor-1 expression in thrombosis and thrombolysis of a rabbit model of traumatic deep vein thrombosis. Chin J Tissue Eng Res 16:7929–7932
29.
Zurück zum Zitat Franciscis S, Gallelli L, Amato B, Butrico L, Rossi A, Buffone G, Caliò FG, De Caridi G, Grande R, Serra R (2016) Plasma MMP and TIMP evaluation in patients with deep venous thrombosis: could they have a predictive role in the development of post-thrombotic syndrome? Int Wound J 13(6):1237–1245CrossRefPubMed Franciscis S, Gallelli L, Amato B, Butrico L, Rossi A, Buffone G, Caliò FG, De Caridi G, Grande R, Serra R (2016) Plasma MMP and TIMP evaluation in patients with deep venous thrombosis: could they have a predictive role in the development of post-thrombotic syndrome? Int Wound J 13(6):1237–1245CrossRefPubMed
30.
Zurück zum Zitat Hänze J, Weissmann N, Grimminger F, Seeger W, Rose F (2007) Cellular and molecular mechanisms of hypoxia-inducible factor driven vascular remodeling. Thromb Haemost 97(5):774–87PubMed Hänze J, Weissmann N, Grimminger F, Seeger W, Rose F (2007) Cellular and molecular mechanisms of hypoxia-inducible factor driven vascular remodeling. Thromb Haemost 97(5):774–87PubMed
Metadaten
Titel
MiR-411 suppressed vein wall fibrosis by downregulating MMP-2 via targeting HIF-1α
verfasst von
Peng Ai
Bangli Shen
Hao Pan
Kui Chen
Jihang Zheng
Fengjun Liu
Publikationsdatum
20.12.2017
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 2/2018
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-017-1596-8

Weitere Artikel der Ausgabe 2/2018

Journal of Thrombosis and Thrombolysis 2/2018 Zur Ausgabe

EditorialNotes

A legacy of words

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.